Single-fraction HDR brachytherapy combined with SBRT for intermediate and high-risk prostate cancer: Oncologic and patient-reported outcomes from a prospective phase II study
Abstract
Purpose: Brachytherapy boost is an established dose-escalation strategy in intermediate- and high-risk prostate cancer, while stereotactic body radiotherapy (SBRT) offers treatment efficiency with favourable radiobiology. We report mature results of a prospective phase II trial combining single-fraction high-dose-rate (HDR) brachytherapy with prostate-only SBRT.
Materials and methods: Seventy-six patients with intermediate- or high-risk prostate cancer were enrolled between 2019 and 2021. Treatment consisted of MRI-TRUS fusion HDR brachytherapy (15 Gy, single fraction) followed by SBRT (25 Gy in 5 fractions). Androgen deprivation therapy was prescribed according to risk group. The primary endpoint was patient-reported quality of life (EPIC-26, EORTC QLQ-PR25). Secondary endpoints included acute and late genitourinary (GU) and gastrointestinal (GI) toxicity (CTCAE v5), PSA response, biochemical relapse-free survival (bRFS), metastasis-free survival (MFS), and overall survival (OS).
Results: With a median follow-up of 48 months, no acute or late grade 3 GI toxicity was observed. Two patients (2.6 %) developed late grade 3 GU toxicity. Acute and late grade 2 GU toxicity occurred in 11.8 % and 28.9 % of patients, respectively. Urinary and bowel quality of life showed a transient and non-significant decline at one month, returning to baseline by six months. The median PSA nadir was 0.04 ng/mL. The 4-year bRFS and MFS were both 91 % (95 % CI 84-98 %). The median PSA at 4 years was…
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.